IVERIC bio
ISEE
ISEE was delisted on the 10th of July, 2023.
213 hedge funds and large institutions have $2.26B invested in IVERIC bio in 2022 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 68 increasing their positions, 64 reducing their positions, and 28 closing their positions.
162% more call options, than puts
Call options by funds: $186M | Put options by funds: $70.8M
104% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 28
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
28% more capital inflows, than outflows
Capital inflows: $499M | Capital outflows: $389M
16% more funds holding
Funds holding: 184 → 213 (+29)
4.03% more ownership
Funds ownership: 102.46% → 106.49% (+4%)
6% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 64
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RTW Investments
New York
|
+$47.6M |
| 2 |
Deep Track Capital
Greenwich,
Connecticut
|
+$32.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31.3M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$29.6M |
| 5 |
Redmile Group
San Francisco,
California
|
+$24.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vivo Capital
Palo Alto,
California
|
-$62.4M |
| 2 |
Janus Henderson Group
London,
|
-$39.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$32.7M |
| 4 |
Commodore Capital
New York
|
-$23.2M |
| 5 |
Yiheng Capital Management
San Francisco,
California
|
-$19M |
ISEE Hedge Fund Activity: Q3 2022 in Review
213 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio (ISEE) for Q3 2022, worth a combined $2.26B — up 97% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new ISEE positions and 28 closed out — a net gain of 29 holders — while 68 added to existing stakes and 64 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $47.6M. The largest seller was Vivo Capital, cutting an estimated $62.4M.
- 213 institutional investors held IVERIC bio (ISEE) as of Q3 2022, up from 184 in Q2 2022.
- Funds reported $2.26B of IVERIC bio stock for Q3 2022, up 97% quarter-over-quarter.
- 57 funds opened new IVERIC bio positions in Q3 2022 and 28 closed out, a net change of +29 holders.
- The largest IVERIC bio buyer in Q3 2022 was RTW Investments, an estimated $47.6M added.
- The largest IVERIC bio seller in Q3 2022 was Vivo Capital, an estimated $62.4M sold.
Based on aggregated 13F filings for Q3 2022.